EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

Ta-Chiang Liu, Evanthia Galanis, David Kirn

Nature Clinical Practice Oncology · 2007-02 · 4 (2) · 101-117

DOI: 10.1038/ncponc0736 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Clinical Practice Oncology, 2007-02. Verfasst von Ta-Chiang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Jennerex Biotherapeutics, One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 383-mal zitiert (Crossref) und nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic oncolytic viruses (virotherapeutics) constitute a novel class of targeted anticancer agents that have unique mechanisms of action compared with other cancer therapeutics. The development of virotherapeutics has evolved from the use of in vitro-passaged strains (first generation), to genetically engineered selectivity-enhanced viruses (second generation) and finally to genetically engineered transgene-expressing 'armed' oncolytic viruses (third generation). Descriptions of cancer remissions following virus infections date back to a century ago. Initial patient treatment publications, written up to 50 years ago, consisted of case reports or case series of treatment with first-generation, non-engineered viruses. Over the past decade, hundreds of patients with cancer have been treated on prospectively designed clinical trials (including phase III), evaluating over 10 different agents, inlcluding engineered second-generation and third-generation viruses. This Review summarizes and interprets the data from clinical reports over the last century, including safety, efficacy and biological end points (viral and immunologic). Systemic safety and efficiacy has been clearly demonstrated with some virotherapeutics. The implications of these data for future virotherapy development are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicGenetic EngineeringHumansNeoplasmsOncolytic VirotherapyTransgenes

Autor:innen und Institutionen

  • Jennerex Biotherapeutics, One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA.

Zitieren

APA

Liu, T. C., Galanis, E., & Kirn, D. (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nature Clinical Practice Oncology, 4(2), 101-117. https://doi.org/10.1038/ncponc0736

Vancouver

Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nature Clinical Practice Oncology. 2007;4(2):101-117. doi:10.1038/ncponc0736

BibTeX
@article{Liu2007,
  author = {Liu, Ta-Chiang and Galanis, Evanthia and Kirn, David},
  title = {Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress},
  journal = {Nature Clinical Practice Oncology},
  year = {2007},
  volume = {4},
  number = {2},
  pages = {101--117},
  doi = {10.1038/ncponc0736}
}
Kostenlos starten →